Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com
2024-03-13
疫苗
DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering.
'Royalty Rates in Pharmaceutical and Biotechnology Deals'
Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2024.
The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.
Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.
Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.
Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.
In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:
Understand royalty rate trends since 2010
Analysis of the structure of royalty clauses with real life case studies
Browse collaboration and licensing deals which reveal a royalty rate
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Analyzing actual contract agreements allows assessment of the following:
What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
1.1. What are royalties?
1.2. History of royalty rates
1.3. Royalties in pharmaceuticals and biotechnology
1.4. Royalties versus revenue share
1.5. Overview of the report
Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates
2.1. Trends in royalty rates 2010 - 2024
2.2. How do revenue shares figure?
2.3. A review of recent literature
2.4. Royalty rates in the future
Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals
3.1. Partnering agreement structure
3.2. Structure of a typical royalty clause
3.3. Example royalty clauses
3.3.1. Case study 1
3.3.2. Case study 2
3.3.3. Case study 3
3.3.4. Case study 4
Chapter 4 - Companies actively disclosing royalty rates
4.1. Most active companies in disclosing royalty rates
Chapter 5 - Royalty rate contract directory
Explore royalty rates within the deal contract document to gain greater insight
Deal directory
Deal Directory - Royalty rates in deals - by company A-Z
Deal Directory - Royalty rates in deals - by therapy area
Deal Directory - Royalty rates in deals - by stage of development at signing
Deal Directory - Royalty rates in deals - by technology type
Royalty rate references
Example royalty rate deal contract document
List of Figures
Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2024
Figure 2: Components of the partnering deal structure
Figure 3: Components of the partnering royalty clause
Figure 4: Most active companies disclosing royalty rate 2010 - 2024
Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies
Companies Mentioned
2seventy bio
3a-diagnostics
4SC
Actavis (acquired by Watson)
Active Biomaterials
Adaptimmune
Adlai Nortye
Advanced Dosage Forms
Advaxis
Advirna
AEterna Zentaris
Afritex Medical Products
Aguettant
Alchemia
Alfa Wassermann
Allergan
Almirall
Alternavida
Altman Enterprises
AltrazealTrading
American Type Culture Collection (ATCC)
Amyris
AnnaMed
Antigen Express
Aradigm
Arctic Vision
Arvinas
Astellas Pharma Europe
Athenex
Authentic Brands Group
Baliopharm
BeiGene
Beijing Defengrei Biotechnology
Belgian Volition
BioGene Technology
Biopharmex
Bioprocess Capital Ventures
BioProspect
Biostem US
Biotechnology Value Fund
Blueprint Medicines
Cannus Partners
CB2 Therapeutics
Cellvera
Celyad
Cereal Ingredients
CGA 369
cGreen
Chi-Med
Chiesi Farmaceutici
Chong Kun Dang
Chongqing Jingdong Pharmaceutical
Clal Biotech
CMIC
CohBar
Cohen-McNiece Foundation
Common Sense
Concile
Consilient Health
ContraFect
Cosmofix
Crossject
CSL
Cures Within Reach
Curis
Cybin
Cytokinetics
Daiichi Sankyo
Dana-Farber Cancer InstituteCancer Institute
Dance Biopharm
Dermin
Dr. Falk Pharma
Dr. Reddy's Laboratories
DRI Capital
Drugs for Neglected Diseases Initiative
Eczacibasi Pharmaceuticals
Egalet
Elencee
Endocyte
EnGeneIC
Entest BioMedical
EnWave
Epizyme
Epocal
Evolva
Exelixis
Eyevance
Fairview Health System
Fox Chase Chemical Diversity Center
FusionVax
Genfit
Geron
Government of Israel
GPCR TherapeuticsGPCR Therapeutics
Gravocore
Hai Kang Life
Hail First Pharma
Health Canada
Health Discovery
Heartseed
Heat Biologics
Hefei Life Science
Hefei Tianhui Incubation of Technologies
HekaBio
HemoCleanse
Hemogenyx
HemPup
Henlius Biotech
Hoffmann La Roche
I-mab
Ice + Jam
IDC-GP Pharm
Immunic
iNAP
Internet Marketing Consortium
Intuitive Surgical
Ipsen
Israeli National Authority for Technological Innovation
Ivantis
John Morley Foods
Journey Medical
Jupiter Wellness
K2M
Kensey Nash
Kieran Murphy
Kinetic Concepts
Klaria
Knighton Foods
Kowa
KVK-Tech
Kyowa Hakko Kirin
L1 Systems
Laboratories Acbel
Lee Moffitt Cancer Center
Level Brands
Link Health
Lipidor
Lipocine
Lorna Linda University
Lubrizol
Lumenis
Lundbeck
Macrogenics
MainPointe
Marvanal
Marv Enterprises
McEwen Centre for Regenerative Medicine
Meda
Medica Avante
Medical Technologies Innovation Asia
Medice Arzneimittel Putter
Medicines Patent Pool Foundation
Medicox
MediGene
Medigus
MedImmune
Medivation
Melmed
Memory Dx
Merck and Co
Merus
Methodist Hospital Houston
Micromet
Millennium
Mimi's Rock
Labor and Welfare
Mitsubishi Tanabe Pharma
Moderna
Morgan Stanley
Mount Sinai Health System
Munich Leukemia LaboratoryLeukemia Laboratory
NanoViricides
National Green Biomed
Neotope
Nephrogenex
Nephros
Neuraxpharm
NeuroVive Pharmaceutical Asia
Notable Labs
Novocure
Nucorion
Numab
Nunzi Pharmaceutical
NutraOrigin
NXTGEN
Oberland Capital
Omeros
Oncologie
Onegevity
One Way Liver Genomics (OWL)
Orgenesis
Orion
Orox Pharmaceuticals
Otsuka
Pan-Provincial Vaccine Enterprise
Pharmastrip
Phosphagenics
Phusion Laboratoies
Phyto Nutricare
Pozen
PreMD
Professional Compounding Centers of America
Prosidion
Puma BiotechnologyPuma Biotechnology
QRxPharma
Reedy Creek Investments
RegenaStem
RenalytixAI
Resarci Therapeutics
Retrophin
RST Biomedikal Sanayi
SACCO
Sam Amer
Sanpellegrino Cosmetics
Sapientia Pharmaceuticals
Schrodinger
Seagen
Senetek
Senior Paradise
Sensory Cloud
Shionogi
Skinvera
Soliance
STADA Arzneimittel
Sucampo AG
Synergy Strips
Tactical Relief
Taiba
Taiho
TB Alliance
Technion Research and Development Foundation
Teijin
Tesaro
Theravance
The Regents of the University of California
Tilray
Titterington Veterinary Services
Tramorgan
Transgene
Trevena
TrovaGene
TTFactor
Uluru
UniQure
Universal Cells
University Health Network
UOP
Uppsalagruppen Medical
ValiPharma
Valneva
Vaxent
Veracyte
Virbac
Voronoi
Wisconsin Alumni Research Foundation
World Class Extractions
WUGEN
Yeugnam University
Yissum Research Development
Zenitech
For more information about this report visit https://www.researchandmarkets.com/r/pilfnx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。